For your patients with stage II/III HR+/HER2- eBC at high risk of recurrence,

Start with KISQALI 400 mg—the starting dose chosen to reduce both the risk of recurrence and dose-dependent adverse reactions

• KISQALI is given as 400 mg (2 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 36 months with an AI¹

  • Review the full Prescribing Information for recommended dosing of selected AI 

  • An LHRH agonist should be used concomitantly with AI in men and premenopausal women

  • Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity

  • KISQALI can be taken with or without food

  • Patients may store at room temperature at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)

  • Store in the original blister package in order to protect from moisture

Starting dose modification for severe renal impairment¹

• The recommended starting dose is 200 mg once daily for patients with severe renal impairment

AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone.